The Opportunity for Diagnostics in Bacterial Meningitis across Africa
Tarisiro Matiza
April 2, 2026
Market Access Africa | Diagnostics Landscape Assessment
A generation ago, meningitis tore through sub-Saharan Africa with devastating consequences. Entire communities in countries stretching from Senegal to Ethiopia - a region known as the “meningitis belt” - faced annual outbreaks, and they had limited tools to fight back. Then came MenAfriVac, a vaccine developed specifically for the meningitis belt and rolled out across the region from 2010.
The results were remarkable. Over 400 million people were vaccinated, and serogroup A meningococcal meningitis was reduced by 99%. Cases that were once numbering in the tens of thousands each year became sporadic. It stands as one of the most successful public health interventions Africa has ever seen.
But the story did not end there. Meningitis itself did not disappear, but rather it adapted. Today, most meningitis cases across the belt are caused by Neisseria meningitidis serogroups C, W, and X, as well as a different bacterium altogether, Streptococcus pneumoniae. These are strains that MenAfriVac was never designed to cover.
In 2025 alone, close to 19,000 cases and 1,000 deaths were reported across the meningitis belt. The Democratic Republic of Congo, Niger, and Nigeria carried the heaviest burden. And beyond deaths, many survivors live permanently with hearing loss, cognitive impairment, and neurological disability. These are consequences that reshape lives and impose lasting costs on health systems and economies.
MenAfriVac was designed to target serogroup A, and it did what it was designed to do - it successfully protected communities against that strain. However, the serogroups now driving disease were always outside the scope of that vaccine; the disease that remains requires a different set of tools.
For people unfamiliar with infectious disease management, it might seem that the most important thing is having the right antibiotic. Indeed, antibiotics are critical; bacterial meningitis is treatable when caught early. But treatment decisions in bacterial meningitis are pathogen specific.
Accurate diagnosis of bacterial meningitis depends on collection and testing of cerebrospinal fluid (CSF) — the fluid that surrounds the brain and spinal cord. This is done through a lumbar puncture, more commonly known as a spinal tap. In a well-equipped hospital, that sample is then analysed in a laboratory (using bacterial culture or PCR testing, protein and glucose measurements). Together, these tests tell clinicians exactly what they are dealing with and informs targeted treatment. In much of the meningitis belt, that full picture is rarely available. And without it, clinicians are often left guessing.
“The turnaround time for PCR tests after being sent to the labs is too long. By the time the results are available, the patient would have been discharged — or unfortunately lost their life.” — Infectious disease clinician, Nigeria
Where diagnostic tools are unavailable, clinicians treat based on symptoms and experience alone. For the individual patient, that means treatment may not be precisely matched to the pathogen causing their illness. For the health system, this means we fail to capture the surveillance data needed to understand and respond to a shifting epidemic.
This is not a failure of individual clinicians. It is a systemic problem - one that Market Access Africa has spent years working to understand and address. Through our work across Cameroon, Malawi, Nigeria, and Senegal, and through deep engagement with clinicians, laboratory specialists, and health system leaders across the continent, we have mapped where the diagnostic pathway breaks down, and why.
Through our research across the meningitis belt, we consistently find the same interconnected systemic challenges; each challenge reinforces the other, and none of them can be addressed in isolation of the other. The tools are often simply not available.
Many medical and laboratory consumables are still procured from manufacturers in high-income countries through local distributors. Despite high volume requirements of consumables by healthcare facilities across the continent, there are few incentives for accessible pricing – escalating the procurement costs of essential tools. This often results in limited access to high quality consumables for sample collection such as lumbar puncture kits, sterile sample storage containers, and laboratory reagents, thereby hindering the capacity of health care facilities for appropriate sampling and accurate diagnosis.
This is further exacerbated by weak supply chains, budget constraints, and stock management challenges which were observable common challenges in many countries, forcing healthcare professionals to improvise with the available tools. This oftens leads to painful procedures for patients, compromised sample quality or empirical management of suspected meningitis cases.
Bacterial culture and PCR testing require specialised equipment and trained personnel. Many district and regional laboratories lack equipment and trained personnel needed to perform bacterial cultures reliably. While PCR testing is available in some tertiary or reference laboratories, it is not routinely accessible due to high costs, infrastructure requirements, and limited testing capacity. As a result, many suspected meningitis cases are never microbiologically confirmed, weakening clinical care, disease surveillance, and outbreak response.
Additionally, advanced testing is concentrated in central laboratories, requiring samples to be transported from remote health facilities to central labs. This not only introduces delays in diagnosis and lifesaving treatment decisions but poses a new set of challenges particularly with sample integrity and preservation, as CSF samples require cold chain storage during transportation, which is often limited in remote facilities, compromising the CSF samples and subsequently affecting accurate diagnosis.
Current molecular diagnostic assays for meningitis cost approximately $200 per patient. For an outbreak of 20,000 suspected cases, that is over $4 million in diagnostic costs alone, before hospital admission, auxiliary tests, or treatment. This is simply not absorbable within the public health budgets of most affected countries, particularly when those budgets must also cover malaria, HIV, tuberculosis, and a range of other priorities.
“Over the past 15 years, we extensively worked with partners to eliminate meningitis across multiple African countries. We experienced a breakthrough with the introduction of a point of care PCR platform — but it was not widely accepted due to the high costs associated with it.” — Infectious disease expert
This observation, shared with our team during field research, captures a broader truth: diagnostic innovation that is technically excellent but financially out of reach will not change outcomes on the ground.
Much of the current infrastructure and funding for meningitis across the belt is oriented toward containing outbreaks once they are already under way. But it means that the quieter, ongoing work of building diagnostic capacity at the district level has been consistently underprioritised forcing health systems to always catch up, rather than getting ahead of the disease.
There is an immense opportunity to transform meningitis care through the introduction of point-of-care (POC) molecular testing platforms. However, the commercially available near POC platforms like the BioFire FilmArray have a limited footprint in Africa, and there are very few molecular assays currently in development.
The most common PCR assay identified in the central and reference laboratories across the 4 countries we evaluated (Cameroon, Malawi, Nigeria and Senegal) is the CDC rt-PCR, which requires transportation from facilities to labs, a process which equally has the associated challenges and contributes to the high turnaround time of results. Evidence from HIV and tuberculosis programmes demonstrates that decentralising testing through POC molecular platforms accelerates treatment decisions. However, to turn this into a reality, funding and clearly articulated demand generation are needed to drive development and commercialization of such diagnostic tools.
Innovation is needed in low-cost, high-quality sample collection and storage tools that preserve CSF without requiring strict cold chain conditions. Clinicians emphasised the need for a sample collection device that allows safe transport of samples from rural healthcare facilities without cold chain, while extending shelf-life of CSF for further testing, genotyping and pathogen surveillance. One approach with real promise is the dry spot card — a card-based medium that preserves biological samples at ambient temperature. Versions of dried blood spot cards exist and are available on the market, such as the Whatman 903 designed for HIV diagnostics. The challenge however lies in adapting the existing tools to suite the fluid nature of CSF samples to enable sample preservation and ultimately accurate and rapid pathogen identification closer to patients in rural and district facilities.
Currently, a research group based in the Malawi Liverpool Wellcome Programme are developing a dry spot card designed specifically for CSF preservation and meningitis-specific molecular assays. The commercialisation of this dry spot card will be a major milestone for improving diagnostic challenges for meningitis and improving patient outcomes. Other dried spot cards currently available include the Capitainer® microsampling cards for whole blood, serum, and urine for various molecular diagnostic applications, pointing to broader potential of this approach.
New diagnostic tools must integrate seamlessly into already overstretched health systems. Devices that require complex workflows, highly specialised staff, or extensive infrastructure are unlikely to be sustained. Simplicity, reliability, and compatibility with current clinical practice are critical for adoption.
With limited public health budgets, diagnostics must be affordable and supported by sustainable procurement models and the supply chain to ensure consistent availability of the required consumables. The current cost of meningitis diagnosis and treatment is too exorbitant to be absorbed by affected African countries given other disease priorities.
Our modelling suggests that the introduction of low-cost, POC diagnostic technologies, supported by clear demand generation and local procurement pathways could reduce the cost of meningitis diagnosis and treatment by up to 90%, making it more sustainable for African governments to absorb. Local manufacturing and regional distribution models also have potential to reduce costs substantially while strengthening supply chains and reducing dependence on distant suppliers.
The epidemiological shift that followed MenAfriVac’s success has created both a challenge and an opportunity. The challenge is that the diagnostic infrastructure built around serogroup A does not adequately address the serogroups now driving disease. The opportunity is that the tools, the evidence base, and the partnerships needed to build something better are increasingly within reach.
What is required now is a deliberate, coordinated effort to invest in affordable diagnostics, decentralise testing capacity, and create the demand signals that bring innovators and manufacturers to this market. Without that effort, healthcare professionals will continue to manage meningitis empirically based on symptoms alone, without the confirmed diagnosis that enables targeted, effective care. The gains of MenAfriVac will be undermined by a lack of the tools needed to understand what is causing illness in the first place.
Strengthening diagnostic access should therefore not be a peripheral concern. It is the foundation on which effective meningitis care and effective outbreak response must be built.
Market Access Africa is a specialist advisory firm focused on improving access to diagnostics and health technologies across sub-Saharan Africa. Our landscape assessments, market entry strategies, and policy engagement work spans infectious disease, maternal health, and non-communicable disease programmes across the continent.
